Write an essay on targeting Epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors or TKIs to treat Patients with Lung cancer and the role of mutations developing resistance and sensitization
Hua
Reading.pptxReading Materials
Román, M. et al. (2018) ‘KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target’, Molecular Cancer. Molecular Cancer, 17(1), pp. 1–14. doi: 10.1186/s12943-018-0789-x.
DONG, Y., REN, W., QI, J., JIN, B., LI, Y., TAO, H., XU, R., LI, Y., ZHANG, Q. & HAN, B. 2016. EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Oncology letters, 11, 2371-2378.
THOMPSON, J. C., YEE, S. S., TROXEL, A. B., SAVITCH, S. L., FAN, R., BALLI, D., LIEBERMAN, D. B., MORRISSETTE, J. D., EVANS, T. L. & BAUML, J. 2016. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clinical Cancer Research, 22, 5772-5782.
Yokota, T. (2012) ‘Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?’, Anti-Cancer Agents in Medicinal Chemistry, 12(2), pp. 163–171. doi: 10.2174/187152012799014968.
Ellison, G. et al. (2013) ‘EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples’, Journal of Clinical Pathology, 66(2), pp. 79–89. doi: 10.1136/jclinpath-2012-201194.
Mutations in the EGFR Pathway | AACC.org. https://www.aacc.org/publications/cln/articles/2013/october/egfr-mutations. Accessed March 14, 2020.
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer - Annals of Oncology. https://www.annalsofoncology.org/article/S0923-7534(19)37561-1/fulltext. Accessed March 14, 2020.
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target | SpringerLink. https://link.springer.com/article/10.1186/s12943-018-0789-x. Accessed March 14, 2020.
Lung Cancer With an EGFR Mutation: Diagnosis and Treatment. https://www.verywellhealth.com/lung-cancer-with-an-egfr-mutation-4097338. Accessed March 14, 2020.
Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, and Head and Neck Cancers | Cancer Network. https://www.cancernetwork.com/oncology-journal/anti-egfr-therapies-clinical-experience-colorectal-lung-and-head-and-neck-cancers. Accessed March 14, 2020.
Brambilla, E., and Gazdar, A. (2009). Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 33, 1485-1497.
Colombino, M., Paliogiannis, P., Cossu, A., Santeufemia, D.A., Sardinian Lung Cancer Study, G., Sini, M.C., Casula, M., Palomba, G., Manca, A., Pisano, M., et al. (2019). EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulm Med 19, 209.
Jorge, S.E., Kobayashi, S.S., and Costa, D.B. (2014). Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 47, 929-939.
Stewart, E.L., Tan, S.Z., Liu, G., and Tsao, M.S. (2015). Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 4, 67-81.
SU, S. & WU, Y.-L. 2017. Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review. Journal of hematology & oncology, 10, 147.
SESHACHARYULU, P., PONNUSAMY, M. P., HARIDAS, D., JAIN, M., GANTI, A. K. & BATRA, S. K. 2012. Targeting the EGFR signaling pathway in cancer therapy. Expert opinion on therapeutic targets, 16, 15-31.
:
Nan, X., Xie, C., Yu, X., and Liu, J. (2017). EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 8, 75712.
Citri, A., and Yarden, Y. (2006). EGF–ERBB signalling: towards the systems level. Nature reviews Molecular cell biology 7, 505-516.
Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology and Physics 59, S21-S26.
Sharma, S.V., Bell, D.W., Settleman, J., and Haber, D.A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 7, 169-181.
Mazza, V., and Cappuzzo, F. (2017). Treating EGFR mutation resistance in non-small cell lung cancer–role of osimertinib. The application of clinical genetics 10, 49.
AF Gazdar. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009 August ; 28(Suppl 1): S24–S31.doi:10.1038/onc.2009.198
AlyssaM.Krasinskas. EGFR Signaling in Colorectal Carcinoma. Pathology Research International Volume 2011, Article ID 932932, 6 pages doi:10.4061/2011/932932
Morgillo F, Della Corte CM, Fasano M, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 2016;1: e000060. doi:10.1136/ esmoopen-2016-000060
Zhenfang Du and Christine M. Lovly. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer (2018) 17:58 https://doi.org/10.1186/s12943-018-0782-4
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent and Ignacio Gil-Bazo. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Molecular Cancer (2018) 17:33 https://doi.org/10.1186/s12943-018-0789-x
Ammad Ahmad Farooqia, Marc de la Rocheb, Mustafa B.A. Djamgozc,d, Zahid H. Siddike. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in Cancer Biology, Volume 58, October 2019, Pages 65-79. https://doi.org/10.1016/j.semcancer.2019.01.001
